Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
Contineum Therapeutics, Inc. Class A (CTNM) Ownership Overview
0.53% Insiders
8.29% Mutual Funds
52.19% Other Institutional Investors
4.66% ETFs
34.32% Public Companies and
Individual Investors
The ownership structure of Contineum Therapeutics, Inc. Class A (CTNM) stock is a mix of institutional, retail, and individual investors. Approximately 65.14% of the company’s stock is owned by Institutional Investors, 0.53% is owned by Insiders, and 34.32% is owned by Public Companies and Individual Investors.
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
Dec 31, 2025 | xxxxxxxxxxxxx | $195155 | |
Dec 31, 2025 | xxxxxxxxxxxxx | $16240178 | |
Dec 31, 2025 | xxxxxxxxxxxxx | $16740286 | |
Dec 31, 2025 | xxxxxxxxxxxxx | $24914096 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,179,711 | Institution | 6.67% | 26,614,271 | |
| 1,464,592 | Institution | 4.48% | 17,882,668 | |
| 1,420,838 | Institution | 4.35% | 17,348,432 | |
| 1,116,153 | Institution | 3.42% | 13,628,228 | |
| 1,114,886 | Institution | 3.41% | 13,612,758 | |
| 582,279 | Institution | 1.78% | 7,109,627 | |
| 542,628 | Institution | 1.66% | 6,625,488 | |
| 450,000 | Institution | 1.38% | 5,494,500 | |
| 280,000 | Institution | 0.86% | 3,418,800 | |
| 259,415 | Institution | 0.79% | 3,167,457 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 1,114,886 | Institution | 3.41% | 13,612,758 | |
| 582,279 | Institution | 1.78% | 7,109,627 | |
| 450,000 | Institution | 1.38% | 5,494,500 | |
| 280,000 | Institution | 0.86% | 3,418,800 | |
| 171,806 | Institution | 0.53% | 2,097,751 | |
| 49,280 | Institution | 0.15% | 601,709 | |
| 16,648 | Institution | 0.05% | 203,272 | |
| 15,969 | Institution | 0.05% | 194,981 | |
| 13,802 | Institution | 0.04% | 168,522 | |
| 11,300 | Institution | 0.03% | 137,973 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 910,659 | Institution | 2.79% | 13,969,509 | |
| 205,494 | Institution | 0.63% | 3,152,278 | |
| 180,809 | Institution | 0.55% | 2,207,678 | |
| 92,309 | Institution | 0.28% | 1,117,862 | |
| 44,568 | Institution | 0.14% | 544,175 | |
| 29,806 | Institution | 0.09% | 360,951 | |
| 16,163 | Institution | 0.05% | 197,512 | |
| 10,716 | Institution | 0.03% | 129,771 | |
| 10,500 | Institution | 0.03% | 127,155 | |
| 1,762 | Institution | <0.01% | 21,338 |
FAQ
Who Owns Contineum Therapeutics, Inc. Class A (CTNM)?
According to the latest TipRanks data, approximately 52.19% of the company's stock is held by institutional investors, 0.53% is held by insiders, and 34.32% is held by retail investors.
What percentage of Contineum Therapeutics, Inc. Class A (CTNM) stock is held by institutional investors?
According to the latest TipRanks data, approximately 52.19% of Contineum Therapeutics, Inc. Class A (CTNM) stock is held by institutional investors.
What percentage of Contineum Therapeutics, Inc. Class A (CTNM) stock is held by retail investors?
According to the latest TipRanks data, approximately 34.32% of Contineum Therapeutics, Inc. Class A (CTNM) stock is held by retail investors.
Who owns the most shares of Contineum Therapeutics, Inc. Class A (CTNM)?
Peter Kolchinsky owns the most shares of Contineum Therapeutics, Inc. Class A (CTNM).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.